Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion.

Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B.

J Infect Dis. 2012 Mar 1;205(5):763-71. doi: 10.1093/infdis/jir835. Epub 2012 Jan 31.

PMID:
22293431
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The role of neutralizing antibodies in hepatitis C virus infection.

Edwards VC, Tarr AW, Urbanowicz RA, Ball JK.

J Gen Virol. 2012 Jan;93(Pt 1):1-19. doi: 10.1099/vir.0.035956-0. Epub 2011 Nov 2. Review.

PMID:
22049091
[PubMed - indexed for MEDLINE]
Free Article
3.

Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance.

Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, Thursz MR.

J Viral Hepat. 2004 Sep;11(5):459-64.

PMID:
15357653
[PubMed - indexed for MEDLINE]
4.

Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, Yi M, Lemon SM, Ball JK, Bukh J, Evans MJ, Fremont DH, Diamond MS.

J Virol. 2011 Jul;85(14):7005-19. doi: 10.1128/JVI.00586-11. Epub 2011 May 4.

PMID:
21543495
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

PMID:
20685314
[PubMed - indexed for MEDLINE]
6.

Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.

Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, Mee C, Soulier E, Royer C, Lambotin M, Grunert F, Dao Thi VL, Dreux M, Cosset FL, McKeating JA, Schuster C, Baumert TF.

Hepatology. 2010 Apr;51(4):1144-57. doi: 10.1002/hep.23445.

PMID:
20069648
[PubMed - indexed for MEDLINE]
7.

Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia.

Liu FC, Chao YC, Hou TY, Chen HC, Shyu RY, Hsieh TY, Chen CH, Chang DM, Lai JH.

Clin Rheumatol. 2008 Apr;27(4):463-7. Epub 2007 Sep 18.

PMID:
17876647
[PubMed - indexed for MEDLINE]
8.

Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection.

Aref S, Sleem T, El Menshawy N, Ebrahiem L, Abdella D, Fouda M, Samara NA, Menessy A, Abdel-Ghaffar H, Bassam A, Abdel Wahaab M.

Hematology. 2009 Oct;14(5):277-81. doi: 10.1179/102453309X439818.

PMID:
19843383
[PubMed - indexed for MEDLINE]
9.

Antibodies to mutated citrullinated vimentin in patients with chronic hepatitis C virus genotype IV infection-related arthropathy.

Zehairy M, Soliman E, Daghaidy A.

Rheumatol Int. 2012 Nov;32(11):3495-501. doi: 10.1007/s00296-011-2193-3. Epub 2011 Nov 9.

PMID:
22068352
[PubMed - indexed for MEDLINE]
10.

Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo.

Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, Leroux-Roels G.

Hepatology. 2008 Dec;48(6):1761-8. doi: 10.1002/hep.22547.

PMID:
19030166
[PubMed - indexed for MEDLINE]
11.

Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature.

Ramos-Casals M, Pares A, Jara LJ, Solans R, Viñas O, Vázquez P, Sánchez-Tapias JM, Rodés J, Font J; HISPAMEC Study Group*.

J Viral Hepat. 2005 Nov;12(6):648-54. Review.

PMID:
16255767
[PubMed - indexed for MEDLINE]
12.

Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection.

Laperche S, Le Marrec N, Girault A, Bouchardeau F, Servant-Delmas A, Maniez-Montreuil M, Gallian P, Levayer T, Morel P, Simon N.

J Clin Microbiol. 2005 Aug;43(8):3877-83.

PMID:
16081925
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

High prevalence of anticardiolipin antibodies in patients with asymptomatic hepatitis C virus infection associated acute ischemic stroke.

Cojocaru IM, Cojocaru M, Iacob SA.

Rom J Intern Med. 2005;43(1-2):89-95.

PMID:
16739869
[PubMed - indexed for MEDLINE]
14.

High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha.

Matsuda J, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M, Syoji S, Miyake K, Yamanaka M.

Am J Gastroenterol. 1995 Jul;90(7):1138-41.

PMID:
7611213
[PubMed - indexed for MEDLINE]
15.

Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes.

Mancini N, Diotti RA, Perotti M, Sautto G, Clementi N, Nitti G, Patel AH, Ball JK, Clementi M, Burioni R.

PLoS One. 2009 Dec 11;4(12):e8254. doi: 10.1371/journal.pone.0008254.

PMID:
20011511
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Neutralizing antibodies in hepatitis C virus infection.

Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF.

World J Gastroenterol. 2007 Sep 28;13(36):4824-30. Review.

PMID:
17828813
[PubMed - indexed for MEDLINE]
Free Article
17.

Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection.

Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, Moradpour D, Negro F, Desmeules J; Swiss Hepatitis C Cohort Study Group.

J Viral Hepat. 2012 Aug;19(8):568-73. doi: 10.1111/j.1365-2893.2011.01578.x. Epub 2012 Jan 26.

PMID:
22762141
[PubMed - indexed for MEDLINE]
18.

Anti-C1q antibodies in hepatitis C virus infection.

Saadoun D, Sadallah S, Trendelenburg M, Limal N, Sene D, Piette JC, Schifferli JA, Cacoub P.

Clin Exp Immunol. 2006 Aug;145(2):308-12.

PMID:
16879251
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.

Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL.

J Virol. 2005 Jul;79(13):8217-29.

PMID:
15956567
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus.

Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC.

Gastroenterology. 2009 Jun;136(7):2377-86. doi: 10.1053/j.gastro.2009.02.080. Epub 2009 Mar 17.

PMID:
19303013
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk